Bempegaldesleukin (BEMPEG/NKTR-214)

Has anyone heard of this? Really interesting mechanism. Came across it from here. https://ascopubs.org/doi/full/10.1200/JCO.21.00675 PURPOSE Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma. METHODS A total of 41... Read more
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums